Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Distribution: Overview

Drug Distribution: Overview

Drug distribution within the body is a dynamic process involving the movement of a drug in two directions across various compartments: from the bloodstream into tissues (tissue uptake) and from tissues back into the bloodstream (tissue release or redistribution). This process is passive and primarily driven by two variables: the concentration gradient between the bloodstream and the extravascular tissues and the drug's ability to cross the cell membrane.
Initially, the free drug in the...

Drug Dissolution: Requirements and Profile Comparison

The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...

Pharmaceutical Equivalents

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Excess mortality among relocated institutionalized elderly after the Fukushima nuclear disaster.

Public health·2012

Same author

The global drug gap: policy implications for microbicides.

AIDS (London, England)·2001

Same author

Schistosoma haematobium.

The New England journal of medicine·2001

Same author

Abortion trends in Japan, 1975-95.

Studies in family planning·2001

Same author

Public-private partnerships for public health.

Nature medicine·2000

Same author

Electrocardiographic assessment of antianxiety medication in dogs and correlation with serum drug concentration.

Journal of the American Veterinary Medical Association·2000

Search research articles

Related Experiment Video

Updated: Jul 18, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

The global drug gap.

¹Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA. reich@hsph.harvard.edu

Science (New York, N.Y.)

|February 7, 2001

Summary

Global drug access inequities persist due to market failures and income gaps. Addressing this requires policies combining research subsidies, financial incentives, and institutional improvements for essential, new, and future medicines.

Area of Science:

Global Health
Pharmaceutical Policy
Health Economics

Background:

Significant global inequities exist in access to pharmaceutical products between high-income and low-income countries.
These disparities stem from a combination of market failures, government shortcomings, and substantial income differentials.
The global drug gap affects access to essential, new, and yet-to-be-developed medicines.

Purpose of the Study:

To outline policy recommendations for addressing the global drug gap.
To propose a multi-faceted policy approach combining different intervention types.
To balance the need for research and development incentives with equitable access to medicines.

Main Methods:

Policy analysis framework integrating push, pull, and process approaches.

Keywords:

Health Care and Public Health

More Related Videos

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

Published on: November 4, 2022

Related Experiment Videos

Last Updated: Jul 18, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

Published on: November 4, 2022

Review of existing literature on pharmaceutical access and innovation.

Conceptualization of integrated policy solutions.

Main Results:

A comprehensive policy framework is necessary, not a single solution.
Policies must address distinct categories of pharmaceutical products (essential, new, future).
Integration of push (subsidies), pull (market guarantees), and process (institutional capacity) strategies is recommended.

Conclusions:

Addressing global drug access inequities requires a combination of targeted R&D support and market-based incentives.
Strengthening institutional capacity is crucial for effective policy implementation.
Balancing innovation incentives with equitable access is achievable through strategic policy design.